Hence, our findings emphasize the need for future longitudinal studies tracking brain serial TSPO levels from coma onset in relation to neurological performance over time, aiming to understand whether these neuroimmune signatures persist, progress and/or warrant neuroimmune-modulating interventions. This evidence concerns the gene TSPO and type 2 diabetes mellitus.